181 related articles for article (PubMed ID: 22241513)
1. Esomeprazole for the treatment of GERD in infants ages 1-11 months.
Winter H; Gunasekaran T; Tolia V; Gottrand F; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2012 Jul; 55(1):14-20. PubMed ID: 22241513
[TBL] [Abstract][Full Text] [Related]
2. Esomeprazole for the Treatment of GERD in Infants Ages 1-11 Months.
Winter H; Gunasekaran T; Tolia V; Gottrand F; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S9-15. PubMed ID: 26422097
[TBL] [Abstract][Full Text] [Related]
3. Esomeprazole for the Treatment of GERD in Infants Ages 1-11 Months.
Winter H; Gunasekaran T; Tolia V; Gottrand F; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S9-15. PubMed ID: 26121349
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease.
Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2008 May; 46(5):524-33. PubMed ID: 18493207
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD.
Winter H; Kum-Nji P; Mahomedy SH; Kierkus J; Hinz M; Li H; Maguire MK; Comer GM
J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):609-18. PubMed ID: 20400912
[TBL] [Abstract][Full Text] [Related]
7. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
[TBL] [Abstract][Full Text] [Related]
8. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.
Gold BD; Gunasekaran T; Tolia V; Wetzler G; Conter H; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):520-9. PubMed ID: 18030228
[TBL] [Abstract][Full Text] [Related]
9. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2010 Nov; 51(5):593-8. PubMed ID: 20706150
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
Orenstein SR; Hassall E; Furmaga-Jablonska W; Atkinson S; Raanan M
J Pediatr; 2009 Apr; 154(4):514-520.e4. PubMed ID: 19054529
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole reduces gastroesophageal reflux after beer consumption in healthy volunteers.
Franke A; Hepp C; Harder H; Beglinger C; Singer MV
Scand J Gastroenterol; 2008; 43(12):1425-31. PubMed ID: 18924018
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26422093
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
Higginbotham TW
Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
[TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26121345
[TBL] [Abstract][Full Text] [Related]
15. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.
Johnson DA; Orr WC; Crawley JA; Traxler B; McCullough J; Brown KA; Roth T
Am J Gastroenterol; 2005 Sep; 100(9):1914-22. PubMed ID: 16128933
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease.
Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):530-7. PubMed ID: 18030229
[TBL] [Abstract][Full Text] [Related]
17. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS--a cluster-randomized trial.
Moayyedi P; Armstrong D; Hunt RH; Lei Y; Bukoski M; White RJ
Am J Gastroenterol; 2010 Nov; 105(11):2341-6. PubMed ID: 20842110
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD.
Hussain S; Kierkus J; Hu P; Hoffman D; Lekich R; Sloan S; Treem W
J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):226-36. PubMed ID: 24121146
[TBL] [Abstract][Full Text] [Related]
19. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial.
Kiljander TO; Harding SM; Field SK; Stein MR; Nelson HS; Ekelund J; Illueca M; Beckman O; Sostek MB
Am J Respir Crit Care Med; 2006 May; 173(10):1091-7. PubMed ID: 16357331
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux.
Reichel O; Dressel H; Wiederänders K; Issing WJ
Otolaryngol Head Neck Surg; 2008 Sep; 139(3):414-20. PubMed ID: 18722223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
